460 related articles for article (PubMed ID: 10907648)
21. Whole blood harvested after granulocyte-colony stimulating factor (Neupogen) mobilization, and reinfused unprocessed after high-dose melphalan treatment, accelerates hematopoietic recovery in patients with multiple myeloma.
Raina V; Sharma A; Kumar R; Bhargava M
Cancer; 1996 Mar; 77(6):1073-8. PubMed ID: 8635126
[TBL] [Abstract][Full Text] [Related]
22. Hematopoietic stem cells from poor and good mobilizers are qualitatively equivalent.
Jiang L; Malik S; Litzow M; Gastineau D; Micallef I; Roy V; Solberg L; Zubair AC
Transfusion; 2012 Mar; 52(3):542-8. PubMed ID: 21827503
[TBL] [Abstract][Full Text] [Related]
23. Factors affecting hemopoietic recovery after high-dose therapy and autologous peripheral blood progenitor cell transplantation: a single center experience.
Olivieri A; Offidani M; Montanari M; Ciniero L; Cantori I; Ombrosi L; Masia CM; Centurioni R; Mancini S; Brunori M; Leoni P
Haematologica; 1998 Apr; 83(4):329-37. PubMed ID: 9592983
[TBL] [Abstract][Full Text] [Related]
24. Hematopoietic potential and retroviral transduction of CD34+ Thy-1+ peripheral blood stem cells from asymptomatic human immunodeficiency virus type-1-infected individuals mobilized with granulocyte colony-stimulating factor.
Junker U; Moon JJ; Kalfoglou CS; Sniecinski I; Forman SJ; Zaia JA; Kaneshima H; Böhnlein E
Blood; 1997 Jun; 89(12):4299-306. PubMed ID: 9192752
[TBL] [Abstract][Full Text] [Related]
25. Failure to achieve a threshold dose of CD34+CD110+ progenitor cells in the graft predicts delayed platelet engraftment after autologous stem cell transplantation for multiple myeloma.
Wallington-Beddoe CT; Gottlieb DJ; Garvin F; Antonenas V; Sartor MM
Biol Blood Marrow Transplant; 2009 Nov; 15(11):1386-93. PubMed ID: 19822297
[TBL] [Abstract][Full Text] [Related]
26. Autologous transplantation of mobilized peripheral blood CD34+ cells selected by immunomagnetic procedures in patients with multiple myeloma.
Abonour R; Scott KM; Kunkel LA; Robertson MJ; Hromas R; Graves V; Lazaridis EN; Cripe L; Gharpure V; Traycoff CM; Mills B; Srour EF; Cornetta K
Bone Marrow Transplant; 1998 Nov; 22(10):957-63. PubMed ID: 9849692
[TBL] [Abstract][Full Text] [Related]
27. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma.
Arora M; Burns LJ; Barker JN; Miller JS; Defor TE; Olujohungbe AB; Weisdorf DJ
Biol Blood Marrow Transplant; 2004 Jun; 10(6):395-404. PubMed ID: 15148493
[TBL] [Abstract][Full Text] [Related]
28. Selection and transplantation of autologous CD34+ B-lineage negative cells in advanced-phase multiple myeloma patients: a pilot study.
Lemoli RM; Martinelli G; Olivieri A; Motta MR; Rizzi S; Terragna C; Leopardi G; Benni M; Ronconi S; Cantori I; Rondelli D; Mangianti S; Leoni P; Montanari M; Cavo M; Tura S
Br J Haematol; 1999 Nov; 107(2):419-28. PubMed ID: 10583236
[TBL] [Abstract][Full Text] [Related]
29. Cytokine-mobilized peripheral blood CD34+Thy-1+Lin- human hematopoietic stem cells as target cells for transplantation-based gene therapy.
Chen BP; Fraser C; Reading C; Murray L; Uchida N; Galy A; Sasaki D; Tricot G; Jagannath S; Barlogie B
Leukemia; 1995 Oct; 9 Suppl 1():S17-25. PubMed ID: 7475307
[TBL] [Abstract][Full Text] [Related]
30. Clinical and molecular follow-up by amplification of the CDR-III IgH region in multiple myeloma patients after autologous transplantation of hematopoietic CD34+ stem cells.
Martinelli G; Terragna C; Lemoli RM; Cavo M; Benni M; Motta MR; Amabile M; Ottaviani E; Testoni N; de Vivo A; Tura S
Haematologica; 1999 May; 84(5):397-404. PubMed ID: 10329917
[TBL] [Abstract][Full Text] [Related]
31. A comparison of CD34+ cell selected and unselected autologous peripheral blood stem cell transplantation for multiple myeloma: a case controlled analysis.
Gandhi M; Jestice H; Scott M; Bloxham D; Bass G; Craig J; Marcus R
Bone Marrow Transplant; 1999 Aug; 24(4):369-75. PubMed ID: 10467325
[TBL] [Abstract][Full Text] [Related]
32. CD34+ cell enrichment for autologous peripheral blood stem cell transplantation by use of the CliniMACs device.
Després D; Flohr T; Uppenkamp M; Baldus M; Hoffmann M; Huber C; Derigs HG
J Hematother Stem Cell Res; 2000 Aug; 9(4):557-64. PubMed ID: 10982256
[TBL] [Abstract][Full Text] [Related]
33. Analysis of platelet recovery after autologous transplantation with G-CSF mobilized CD34+ cells purified from leukapheresis products.
Hermouet S; Niaussat AE; Briec A; Pineau D; Robillard N; Bataille R; Milpied N; Harousseau JL; Mahé B
Hematol Cell Ther; 1997 Dec; 39(6):317-25. PubMed ID: 9497891
[TBL] [Abstract][Full Text] [Related]
34. Factors that influence collection and engraftment of autologous peripheral-blood stem cells.
Bensinger W; Appelbaum F; Rowley S; Storb R; Sanders J; Lilleby K; Gooley T; Demirer T; Schiffman K; Weaver C
J Clin Oncol; 1995 Oct; 13(10):2547-55. PubMed ID: 7595706
[TBL] [Abstract][Full Text] [Related]
35. Factors influencing collection of peripheral blood stem cells in patients with multiple myeloma.
Demirer T; Buckner CD; Gooley T; Appelbaum FR; Rowley S; Chauncey T; Lilleby K; Storb R; Bensinger WI
Bone Marrow Transplant; 1996 Jun; 17(6):937-41. PubMed ID: 8807097
[TBL] [Abstract][Full Text] [Related]
36. Involvement and functional impairment of the CD34(+)CD38(-)Thy-1(+) hematopoietic stem cell pool in myelodysplastic syndromes with trisomy 8.
Nilsson L; Astrand-Grundström I; Anderson K; Arvidsson I; Hokland P; Bryder D; Kjeldsen L; Johansson B; Hellström-Lindberg E; Hast R; Jacobsen SE
Blood; 2002 Jul; 100(1):259-67. PubMed ID: 12070035
[TBL] [Abstract][Full Text] [Related]
37. High-dose therapy in multiple myeloma: effect of positive selection of CD34+ peripheral blood stem cells on hematologic engraftment and clinical outcome.
Patriarca F; Damiani D; Fanin R; Grimaz S; Geromin A; Cerno M; Sperotto A; Silvestri F; Zaja F; Baccarani M
Haematologica; 2000 Mar; 85(3):269-74. PubMed ID: 10702815
[TBL] [Abstract][Full Text] [Related]
38. Viable CD34+/CD133+ blood progenitor cell dose as a predictor of haematopoietic engraftment in multiple myeloma patients undergoing autologous peripheral blood stem cell transplantation.
Hicks C; Wong R; Manoharan A; Kwan YL
Ann Hematol; 2007 Aug; 86(8):591-8. PubMed ID: 17492259
[TBL] [Abstract][Full Text] [Related]
39. CD34(+) cell subsets and long-term culture colony-forming cells evaluated on both autologous and normal bone marrow stroma predict long-term hematopoietic engraftment in patients undergoing autologous peripheral blood stem cell transplantation.
Lanza F; Campioni D; Moretti S; Dominici M; Punturieri M; Focarile E; Pauli S; Dabusti M; Tieghi A; Bacilieri M; Scapoli C; De Angeli C; Galluccio L; Castoldi G
Exp Hematol; 2001 Dec; 29(12):1484-93. PubMed ID: 11750108
[TBL] [Abstract][Full Text] [Related]
40. Effective purging of autologous hematopoietic stem cells using anti-B-cell monoclonal antibody-coated high-density microparticles prior to high-dose therapy for patients with non-Hodgkin's lymphoma.
Webb IJ; Friedberg nW; Gribben JG; Fisher DC; Spitzer T; Neuberg D; Jallow H; Kim H; Houde H; Monroy R; Schmittling R; Freedman AS
Biol Blood Marrow Transplant; 2002; 8(8):429-34. PubMed ID: 12234168
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
